文献速递｜本瑞利珠单抗停药9个月：失败组BEC高于成功组，超五成患者需重启治疗

TL;DR - A small retrospective study found that 52.6% of severe eosinophilic asthma patients who stopped benralizumab restarted biologic therapy after a median of nine months. Rising blood eosinophil counts (BEC), particularly by month nine, may help identify patients at risk of unsuccessful discontinuation.

• The single-center Japanese study followed 19 benralizumab “super-responders” for at least 12 months after stopping treatment.
• Ten patients restarted biologic therapy because of worsening asthma control or eosinophil-related comorbidities; treatment-free maintenance rates were 52.6% at 12 months and 46.8% at 24 months.
• At month nine, median BEC was significantly higher in the failure group than in the successful-discontinuation group: 451.5 versus 111 cells/μL (p=0.034).
• The retrospective design, small cohort, and absence of a continued-treatment control group limit conclusions; larger prospective studies are needed.